Home >  News >  Industry >  Pharma News >  Biological E, ICMR to...

Biological E, ICMR to develop COVID treatment by injecting inactivated SARS-CoV2 in horses

The 'antisera' is yet to undergo human clinical trials to establish its safety and efficacy and the Drugs Controller General of India (DCGI) would be approached soon in this regard, Dr Samiran Panda, the head of epidemiology and communicable diseases at the Indian Council of Medical Research (ICMR) said.;

By - Ruchika Sharma
Published On 2020-10-03 08:31 GMT   |   Update On 2020-10-03 08:31 GMT
Advertisement

Hyderabad: The ICMR in collaboration with a Hyderabad-based biopharmaceutical company has developed "highly purified antisera" prepared by injecting inactivated SARS-CoV2 in horses, which can be a potential treatment for Covid-19.

"The ICMR and Biological E Limited, Hyderabad, have developed highly purified antisera (raised in animals) for prophylaxis and treatment of Covid-19," the apex health research body said on Thursday.

The 'antisera' is yet to undergo human clinical trials to establish its safety and efficacy and Drugs Controller General of India would be approached soon in this regard, Dr Samiran Panda, the head of epidemiology and communicable diseases at the Indian Council of Medical Research (ICMR) said.

Antisera are blood serum high in antibodies against specific antigens and are injected in humans to help kickstart the immune system to fight specific infections. The pre-print version of the study regarding the development of the equine antisera has been posted on Research Square platform.
Advertisement
"The study provides evidence of the potential of generating highly purified F(ab')2 from equines against SARS-CoV-2 that can demonstrate consistent and high neutralization activity. Further, in-vivo testing for efficacy of this indigenously developed, cost effective product will pave the way to clinical evaluation. Additionally, being a donor independent method, this may prove as an efficient alternative to convalescent plasma for treatment of Covid-19 patients," the study paper said.
Earlier such measures were used for controlling several viral and bacterial infections.
"Although, plasma recovered from patients experiencing Covid-19 could serve similar purpose, the profile of antibodies, their efficacy and concentration keep varying from one patient to another and therefore make it an unreliable clinical tool for patient management," the ICMR said in a tweet.
"Standardization achievable through equine sera based treatment modality thus stands out as yet another remarkable public health initiative supported by ICMR in the time of Covid-19," it said.
As part of the study, 10 healthy horses were immunized with inactivated SARS-CoV-2 virus and after 21 days of immunization, plasma samples were tested. The results of the plasma samples indicated presence of indicated the presence of SARS-Co-V2 specific IgG antibodies as detected in ELISA with neutralizing capacity. The study has not yet been peer-reviewed.
Read also: Trivitron Biocard Pro COVID-19 Antigen Rapid testing kits get ICMR nod
Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

CDSCO Panel Defers Biosphere's Colloidal Nano Silver Gel Trial, Seeks Full Data

Fake WHO, Abbott Emails Used in Over Rs 1.1 Crore Scam on Pharma Executive, 2 Nabbed

State Drug Alert: Ciprofloxacin, Lorazepam, Albendazole Among 97 NSQ Samples Flagged in July

USFDA approves Teva Pharma generic Saxenda for weight loss

AbbVie to buy Gilgamesh Pharma Bretisilocin for Major Depressive Disorder

GSK Gepotidacin approved in UK for UTIs in females aged 12 years and older

AstraZeneca Imfinzi application granted priority review by USFDA for resectable early stage gastric, gastroesophageal junction cancers

46 Drug Batches Fail CDSCO Quality Test In July, Details